2013
DOI: 10.1016/j.ejca.2012.12.009
|View full text |Cite
|
Sign up to set email alerts
|

Targeted therapy-induced radiation recall

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1
1

Citation Types

0
33
0
3

Year Published

2013
2013
2024
2024

Publication Types

Select...
7
2

Relationship

0
9

Authors

Journals

citations
Cited by 59 publications
(38 citation statements)
references
References 32 publications
0
33
0
3
Order By: Relevance
“…New targeted therapies do affect the skin in very specific ways. Interestingly, cases of erlotinib-induced radiation recall dermatitis were described in the literature [12,18]. This observation suggests that targeted therapies, particularly tyrosine kinase inhibitors, should be added to the list of radiation recall dermatitis-inducing substances.…”
Section: Discussionmentioning
confidence: 99%
“…New targeted therapies do affect the skin in very specific ways. Interestingly, cases of erlotinib-induced radiation recall dermatitis were described in the literature [12,18]. This observation suggests that targeted therapies, particularly tyrosine kinase inhibitors, should be added to the list of radiation recall dermatitis-inducing substances.…”
Section: Discussionmentioning
confidence: 99%
“…Baroudjian et al [51] describe the occurrence of radiodermatitis (CTCAE grade 2-3) after vemurafenib followed by radiotherapy of the right axillary area and the radiosensitizing effect of vemurafenib has even been connected with the development of a hemopneumothorax. Skin reactions which were classified as radiation recall phenomena and occurred only after vemurafenib with preceding radiotherapy have been documented as a single case each by Levy et al [53] as radiodermatitis, by Wang et al [54] as keratosis pilaris-like dermatitis, by Conen et al [55] as a maculopapular rash with edema and severe erythema and by Braunstein et al [56] as a serious case of ulceration with parallel erythema and scar dehiscence that required vemurafenib discontinuation. In two cases described by Boussemart et al [57] the sequential application of radiotherapy and vemurafenib to treat cutaneous and bone metastases led to the development of delayed skin reactions in the form of a pruriginous erythematous vesicles or a pruriginous rectangular dermatitis.…”
Section: Braf V600 Inhibitors and Radiotherapy Of Nonbrain Metastasismentioning
confidence: 99%
“…The start of vemurafenib between 1 and 42 days (median: 21 days) after the end of radiotherapy has been strongly associated with the occurrence of radiation recall phenomena. Delayed skin reactions classified as radiation recall radiodermatitis were usually observed between 7 and 14 days (median: 7.5 days) after the start of vemurafenib administration [53][54][55][56][57]. Radiation recall cutis verticis gyrata after radiation treatment of the scalp occurred later, between 14 and 28 days (median: 21 days) after start of BRAF inhibitor therapy which had been preceded by whole-brain radiotherapy [62][63]67].…”
Section: Impact Of Dose and Sequence Of Radiation And Braf V600 Inhibitormentioning
confidence: 99%
“…Une réaction inflammatoire en zone irradiée peut apparaître chez les patients déjà irradiés [93]. Une réaction inflammatoire en zone irradiée peut apparaître chez les patients déjà irradiés [93].…”
Section: Complications Et Séquelles Des Thérapies Ciblées Autres Que unclassified